The growth of personalised healthcare
This article was originally published in Clinica
Personalised healthcare, the targeting of treatments to patients with specific genetic profiles, seems to have finally come of age. An example of its emergence into mainstream healthcare is Dutch company Qiagen's recent decision to invest $130m in UK-based molecular diagnostics company DxS, arguably the single biggest investment yet in this nascent sector.
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
Nano-X Imaging is on a mission to disrupt the market for X-ray imaging equipment by offering a low-cost medical imaging service to untapped markets through a network of equipment dotted around the world. However, some shareholders are claiming the company mislead investors.
The test measures the relative level of antibodies, which could aid vaccine rollout.